0.25
3.78%
0.0091
Handel nachbörslich:
.24
-0.01
-4.00%
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Ltd. Proposes Reverse Stock Split - TipRanks
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Australia
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com India
SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks
SciSparc signs LOI to sell entire ownership in MitoCareX - MSN
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - StockTitan
Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Smartgroup Announces Major Shareholding Changes - TipRanks
Science Group PLC Executes Share Buyback - TipRanks
Site Group Plans Massive New Share Issue - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat
CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks
Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
Clearmind, SciSparc slide amid weight-loss study results - MSN
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
UBS Cuts Stake in Spirent Communications - TipRanks
SThree maintains expectations amid tough market conditions. - Research the market
UK recruiter SThree falls on lower Q3 net fee - XM
SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK
Science Group PLC Announces Share Buyback - TipRanks
SThree plc Navigates Market Headwinds in Q3 - TipRanks
SThree Net Fees Fall Amid Challenging Environment - MarketWatch
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Market Watch: SciSparc Ltd (SPRC)’s Noteworthy Drop, Closing at 0.26 - The Dwinnex
Barclays Ups Stake in Spirent Communications - TipRanks
FDA greenlights SciSparc's phase IIb trial for Tourette Syndrome - Investing.com
Are SciSparc Ltd’shares a good deal? - US Post News
SciSparc Advances Tourette Syndrome Drug Trial - TipRanks
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - Marketscreener.com
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - StockTitan
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Sprout Social, Inc. (SPT): Short Seller Sentiment is Bearish on This AI Stock Under $50 - Insider Monkey
Canaccord Genuity stays at 'speculative buy' on Spirent Communications - ShareCast
Shipping Corporation of India (NSE:SCI) stock performs better than its underlying earnings growth over last five years - Simply Wall St
Spirit Tech’s New Securities Hit ASX - TipRanks
Brighton Jones LLC Boosts Stock Position in Sprout Social, Inc. (NASDAQ:SPT) - Defense World
Acadian Asset Management LLC Invests $27,000 in SPAR Group, Inc. (NASDAQ:SGRP) - Defense World
Strix Group First Half 2024 Earnings: UK£0.023 loss per share (vs UK£0.018 profit in 1H 2023) - Simply Wall St
Sappi appoints Graeme Wild as CEO of its South African operations - IOL
Inspire Investing LLC Has $1.19 Million Position in SMART Global Holdings, Inc. (NASDAQ:SGH) - Defense World
SPRC stock touches 52-week low at $0.25 amid sharp annual decline - Investing.com
ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00 - MarketBeat
Spruce Biosciences Inc (SPRB) expanding its growth trajectory ahead - SETE News
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
ARS Pharmaceuticals Inc [SPRY] Records 50-Day SMA of $11.83 - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Trading Up 6.8% - MarketBeat
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Canada
Safire Group Raises $8M in Financing - FinSMEs
UBS Group AG Increases Stake in Spirent Communications - TipRanks
Spruce Biosciences Inc’s results are impressive - US Post News
SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Australia
Atlantic Sapphire Announces Major Rights Issue - TipRanks
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
SciSparc advances phase IIb trial for Tourette Syndrome treatment - Investing.com India
SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Canada
SkinBioTherapeutics Gears Up for Market Launch - TipRanks
Strix Group (LON:KETL) Stock Price Down 5.5% - Defense World
SPRCSciSparc Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
SciSparc advances phase IIb trial for Tourette Syndrome treatment - Investing.com
SciSparc Takes Major Step Forward with IND Application - GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - Marketscreener.com
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - StockTitan
Stryker Stock Declines Despite Completion of care.ai Acquisition - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):